Display options
Cite
Perri F, Pisconti S, Conson M, et al. Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. Onco Targets Ther. 2015;8:1345-9doi: 10.2147/OTT.S75232.
Perri, F., Pisconti, S., Conson, M., Pacelli, R., Della Vittoria Scarpati, G., Gnoni, A., D'Aniello, C., Cavaliere, C., Licchetta, A., Cella, L., Giuliano, M., Schiavone, C., Falivene, S., Di Lorenzo, G., Buonerba, C., Ravo, V., & Muto, P. (2015). Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. OncoTargets and therapy, 81345-9. https://doi.org/10.2147/OTT.S75232
Perri, Francesco, et al. "Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen." OncoTargets and therapy vol. 8 (2015): 1345-9. doi: https://doi.org/10.2147/OTT.S75232
Perri F, Pisconti S, Conson M, Pacelli R, Della Vittoria Scarpati G, Gnoni A, D'Aniello C, Cavaliere C, Licchetta A, Cella L, Giuliano M, Schiavone C, Falivene S, Di Lorenzo G, Buonerba C, Ravo V, Muto P. Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. Onco Targets Ther. 2015 Jun 08;8:1345-9. doi: 10.2147/OTT.S75232. eCollection 2015. PMID: 26089683; PMCID: PMC4467740.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2015 Jun 08;8:1345-9. doi: 10.2147/OTT.S75232. eCollection 2015.

Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.

OncoTargets and therapy

Francesco Perri, Salvatore Pisconti, Manuel Conson, Roberto Pacelli, Giuseppina Della Vittoria Scarpati, Antonio Gnoni, Carmine D'Aniello, Carla Cavaliere, Antonella Licchetta, Laura Cella, Mario Giuliano, Concetta Schiavone, Sara Falivene, Giuseppe Di Lorenzo, Carlo Buonerba, Vincenzo Ravo, Paolo Muto

Affiliations

  1. Medical Oncology Unit, POC S Annunziata, Taranto, Italy.
  2. Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy ; Institute of Biostructures and Bioimaging, National Council of Research, Naples, Italy.
  3. Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
  4. Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
  5. Department of Radiotherapy, Istituto Nazionale per la Cura dei Tumori-Fondazione G. Pascale. IRCCS di Napoli, Naples, Italy.
  6. Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  7. Division of Oncology, Centro di riferimento Oncologico di Basilicata, IRCCS Rionero in Vulture, Potenza, Italy.

PMID: 26089683 PMCID: PMC4467740 DOI: 10.2147/OTT.S75232

Abstract

BACKGROUND: The clinical benefits of postoperative radiation therapy (PORT) for patients with thymoma are still controversial. In the absence of defined guidelines, prognostic factors such as stage, status of surgical margins, and histology are often considered to guide the choice of adjuvant treatment (radiotherapy and/or chemotherapy). In this study, we describe our single-institution experience of three-dimensional conformal PORT administered as adjuvant treatment to patients with thymoma.

METHODS: Twenty-two consecutive thymoma patients (eleven male and eleven female) with a median age of 52 years and treated at our institution by PORT were analyzed. The patients were considered at high risk of recurrence, having at least one of the following features: stage IIB or III, involved resection margins, or thymic carcinoma histology. Three-dimensional conformal PORT with a median total dose on clinical target volume of 50 (range 44-60) Gy was delivered to the tumor bed by 6-20 MV X-ray of the linear accelerator. Follow-up after radiotherapy was done by computed tomography scan every 6 months for 2 years and yearly thereafter.

RESULTS: Two of the 22 patients developed local recurrence and four developed distant metastases. Median overall survival was 100 months, and the 3-year and 5-year survival rates were 83% and 74%, respectively. Median disease-free survival was 90 months, and the 5-year recurrence rate was 32%. On univariate analysis, pathologic stage III and presence of positive surgical margins had a significant impact on patient prognosis. Radiation toxicity was mild in most patients and no severe toxicity was registered.

CONCLUSION: Adjuvant radiotherapy achieved good local control and showed an acceptable toxicity profile in patients with high-risk thymoma.

Keywords: adjuvant treatment; local control; three-dimensional conformal radiotherapy; thymoma; toxicity

References

  1. Ann Thorac Surg. 1992 Aug;54(2):311-5 - PubMed
  2. Semin Thorac Cardiovasc Surg. 2005 Spring;17(1):32-40 - PubMed
  3. J Med Invest. 2008 Feb;55(1-2):17-28 - PubMed
  4. Am J Clin Oncol. 2016 Jun;39(3):223-7 - PubMed
  5. Ann Thorac Surg. 2009 May;87(5):1641-7 - PubMed
  6. Cancer. 1994 Jul 15;74(2):606-17 - PubMed
  7. J Thorac Oncol. 2008 Jan;3(1):75-81 - PubMed
  8. Cancer. 2009 Dec 1;115(23):5413-20 - PubMed
  9. Cancer Treat Rev. 2012 Aug;38(5):540-8 - PubMed
  10. Ann Thorac Surg. 2002 Oct;74(4):1033-7 - PubMed
  11. Front Oncol. 2014 Jan 10;3:330 - PubMed
  12. J Thorac Cardiovasc Surg. 1997 Jan;113(1):55-63 - PubMed
  13. Eur J Cardiothorac Surg. 2007 Jan;31(1):109-13 - PubMed
  14. J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1743-8 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):654-64 - PubMed

Publication Types